Background: Bladder pain syndrome/interstitial cystitis (BPS/IC) can cause pelvic pain, frequent urination, and a strong urge to urinate. These symptoms can significantly reduce quality of life, causing psychological distress, sexual dysfunction, poor sleep quality, decreased work productivity, and increased morbidity. Despite the prevalence of this condition, determining the most effective treatment guidelines for BPS/IC remains a challenge due to the complexity of its pathogenesis. Objective: Understanding cellular and molecular aspects is essential to explore different cell types in changes in function and sensitivity of the urothelial layer and chronic inflammation. Main Ideas: Cellular aspects in the pathogenesis of BPS/IC include Umbrella Cells, Basal and Intermediate Cells, Paraneuron Cells, Myofibroblasts and Telocytes, Detrusor Smooth Muscle Cells, Nerve Cells, Astrocytes, Microglia, CD68+ Macrophages, CD74+ Lymphocytes, Eosinophils, and Mast Cells. Disruption of these cells leads to altered urothelial barrier function, sensitivity, and chronic inflammation. Molecular aspects include chronic inflammation with increases in p38-mitogen activated protein kinase (p38 MAPK), Interleukin-1β (IL-1β), Interleukin-6 (IL-6), Tumor Necrosis Factor-α (TNF-α), Nerve Growth Factor (NGF), Brain-Derived Neurothropic Peptide (BDNF), and other molecules. Conclusion: Changes in the urothelial barrier and bladder wall sensitivity are also significant. Complex interactions between the immune and nervous systems contribute to chronic inflammation through positive feedback. Therefore, this article aims to understand the cellular and molecular aspects that play a role in the pathogenesis of BPS/IC and help provide appropriate treatment.
Published in | International Journal of Clinical Urology (Volume 8, Issue 2) |
DOI | 10.11648/j.ijcu.20240802.11 |
Page(s) | 12-18 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Bladder Pain Syndrome, Interstitial Cystitis, Inflammation
Type of cell | Location | Role in BPS/IC | References |
---|---|---|---|
Umbrella cells | Bladder urothelial surface | The urothelial barrier, which is composed of the E-cadherin protein, tight junction [Zonula occludin], apical surface protein [Uropakin], and trafficking mechanism, can be affected by disruptions in cell structure. Apoptosis of cells can also alter the barrier function. | [27-29] |
Basal and intermediate cells | Bladder urothelial | Disruption of umbrella cells can fail cytodifferentiation | [28, 30] |
Paraneuron cells | Bladder neck and proximal urehtrae urothelial | Increased sensitivity to potentially harmful stimuli in the urethral lumen can lead to reflexive voiding and bladder pain | [31, 32] |
Myofibroblasts and telocytes | More prevalent in lamina propria layer of bladder, but also found in detrusor layer | Enhanced sensitivity in the afferent pathway of Overactive Bladder/Detrusor Overactivity and Interstitial Cystitis is characterized by increased Piezo1-channel and HCN1 channel expression | [33-35] |
Detrusor smooth muscle cells | Detrusor layer | Injecting Botulinum Toxin A and using leukotriene-1 receptor antagonists can inhibit muscle contractions, potentially resolving symptoms in BPS/IC treatment | [36-38] |
Neuron cells | Urothelial and muscular layer of bladder | BPS exhibits heightened density and activity of these peripheral sympathetic fibres | [39-41] |
Astrocytes and microglias | Spinal dorsal horn | The activation of these cells causes allodynia and bladder hyperactivity in cyclophosphamide-induced cystitis and colitis in rat models through the action of IL-1β and BDNF | [42, 43] |
Macrophage CD68+ | Bladder wall and adventitia layer | In the rat model of cyclophosphamide-induced cystitis, there is an increase in the expression of these cells | [44, 45] |
Lymphocyte CD74+ | Bladder wall and adventitia layer | On days 7 and 14, these cells have enhanced expression in both cyclophosphamide- and H2O2-induced cystitis rat models | [44, 46] |
Eosinophils | Lamina propria, bladder wall, and adventitia layer | A few of these cells were seen in a rat model of cystitis induced by H2O2 on days 7 and 14, as well as in a clinical biopsy specimen | [44, 46] |
Mast Cells | Prominent in detrusor layer but also found in lamina propria layer | The infiltration of bladder tissue was observed in a rat model of cystitis induced by H2O2 on days 1 and 14, and also in a clinical biopsy specimen | [44, 47] |
Pathologic Process | Molecular Substances | Reference |
---|---|---|
Chronic inflammation | Increased of: p38 MAPK, IL-6, IL-1β, IL-2, HIF-1α, CRP, TNF-α, VEGF, CXCL10, EGF, IgE, eosinofil protein x, leukotrien E4, and triptase Decreased of: GP51 | [10, 11, 13, 46, 48, 50, 54] |
Urothelial barrier alteration | Increased of: pro apoptotic protein and APF [phosphor-p53, Caspase 3, Bax, Bad] Decreased of: E-Cadherin, CS, UP, ZO-1, Ki-67, IL-8, and HB-EGF | [16, 17, 27, 28, 48, 56] |
Urothelial hypersensivitiy | Increased of: ATP, stretch-activated ATP, alpha-1, TRPV-1, NA, and NGF | [4, 41, 48, 51] |
Bladder wall hypersensitivity | Increased of: NGF, BDNF, TrK | [39, 40, 52] |
Central Sensitization | Increased of: NGF, BDNF, and spinal Fos | [41, 42, 43, 53] |
BPS | Bladder Pain Syndrome |
IC | Interstitial Cystitis |
BDNF | Brain-Derived Neurothropic Peptide |
HCN-1 | Hyperpolarization-Activated Cyclic Nucleotide Gated |
p38MAPK | p38-Mitogen Activated Protein Kinase |
CCXL1 | Chemokine Ligand 1 |
VEGF | Vascular Endothelial Growth Factor |
EGF | Epidermal Growth Factor |
HIF-1α | Hypoxia-Inducible Factor 1α |
CRP | C-reactive Protein |
GP51 | Glicoprotein 51 |
APF | Antiproliferative Factor |
ZO-1 | Zonula Occludin1 |
UP | Uroplakin |
CS | Chondroitin Sulphate |
HB-EGF | Heparin-Binding Epidermal Growth Factor |
NA | Noradrenalin |
NGF | Nerve Growth Factor |
ATP | Adenosine Triphosphate |
TRPV1 | Transient Receptor Potential Cation Channel Subfamily V Member 1 |
BDNF | Brain-Derived Neurothropic Peptide |
TrK | Tyrosine Kinase |
p38 MAPK | p38-Mitogen Activated Protein Kinase |
IL-1β | Interleukin-1β |
IL-6 | Interleukin-6 |
TNF-α | Tumor Necrosis Factor-α |
[1] | Peters, K. & Tennyson, L. Interstitial Cystitis/Bladder Pain Syndrome. 2019. |
[2] | Bjorling, D. E., Wang, Z.-Y. & Bushman, W. Models of inflammation of the lower urinary tract. Neurourol. Urodyn. 2011, Vol 30, 673–682. |
[3] | Anger JT, Dallas KB, Bresee C, De Hoedt AM, Barbour KE, Hoggatt KJ, Goodman MT, Kim J, Freedland SJ. National prevalence of IC/BPS in women and men utilizing veterans health administration data. Front Pain Res [Lausanne]. 2022. Aug 24; 3: 925834. |
[4] | Jhang, J.-F. & Kuo, H.-C. Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease. Int. Neurourol. J. 2016, Vol 20, S95-104. |
[5] | Duh, K. et al. Crosstalk between the immune system and neural pathways in interstitial cystitis/bladder pain syndrome. Discov. Med.25, 2018, 243–250. |
[6] | Friedlander, J. I., Shorter, B. & Moldwin, R. M. Diet and its role in interstitial cystitis/bladder pain syndrome [IC/BPS] and comorbid conditions. BJU Int. 2012, Vol 109, 1584–1591. |
[7] | Vasudevan, V. & Moldwin, R. Addressing quality of life in the patient with interstitial cystitis/bladder pain syndrome. Asian J. Urol. 2017, Vol 4, 50–54. |
[8] | Hanno, P. et al. Bladder pain syndrome international consultation on incontinence. Neurourol. Urodyn. 2010, Vol 29, 191–198. |
[9] | Birder, L. A. Pathophysiology of interstitial cystitis. Int. J. Urol. 2019, Vol 26, 12–15. |
[10] | Jiang, Y.-H., Peng, C.-H., Liu, H.-T. & Kuo, H.-C. Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. PloS One. 2013, Vol8, e76779. |
[11] | Peters, K. M., Diokno, A. C. & Steinert, B. W. Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guérin treat interstitial cystitis by altering the immune profile in the bladder?. Urology, 1999. Vol 54, 450–453. |
[12] | Coppé, J.-P., Desprez, P.-Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 2010, Vol 5, 99–118. |
[13] | Lee, J.-D. & Lee, M.-H. Increased expression of hypoxia-inducible factor-1α and vascular endothelial growth factor associated with glomerulation formation in patients with interstitial cystitis. Urology. 2011, Vol 78, 971. e11-15. |
[14] | Yang, F. et al. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005, Vol 65, 8887–8895. |
[15] | Marazita, M. C., Dugour, A., Marquioni-Ramella, M. D., Figueroa, J. M. & Suburo, A. M. Oxidative stress-induced premature senescence dysregulates VEGF and CFH expression in retinal pigment epithelial cells: Implications for Age-related Macular Degeneration. Redox Biol. 2016, Vol 7, 78–87. |
[16] | Kim, J., Keay, S. K., Dimitrakov, J. D. & Freeman, M. R. p53 mediates interstitial cystitis antiproliferative factor [APF]-induced growth inhibition of human urothelial cells. FEBS Lett. 2007, Vol 581, 3795–3799. |
[17] | Zhang, C.-O., Li, Z.-L. & Kong, C.-Z. APF, HB-EGF, and EGF biomarkers in patients with ulcerative vs. non-ulcerative interstitial cystitis. BMC Urol. 2005, Vol 5, 7. |
[18] | Orabi, H. et al. Tissue engineering of urinary bladder and urethra: advances from bench to patients. Scientific World Journal. 2013, 154564. |
[19] | Khandelwal, P., Abraham, S. N. & Apodaca, G. Cell biology and physiology of the uroepithelium. Am. J. Physiol. Renal Physiol. 2009, Vol 209, F1477-1501. |
[20] | Gevaert, T. et al. Comparative study of the organisation and phenotypes of bladder interstitial cells in human, mouse and rat. Cell Tissue Res. 2017, Vol 370, 403–416. |
[21] | Wolnicki, M., Aleksandrovych, V. & Gil, K. Interstitial cells of Cajal and telocytes in the urinary system: facts and distribution. Folia Med. Cracov. 2016, Vol 56, 81–89. |
[22] | Keast, J. R., Smith-Anttila, C. J. A. & Osborne, P. B. Developing a functional urinary bladder: a neuronal context. Front. Cell Dev. Biol. 2015, Vol 3, 53. |
[23] | Gabella, G. Structure of the intramural nerves of the rat bladder. J. Neurocytol. 1999, Vol 28, 615–637. |
[24] | Traiffort, E., Kassoussi, A., Zahaf, A. & Laouarem, Y. Astrocytes and Microglia as Major Players of Myelin Production in Normal and Pathological Conditions. Front. Cell. Neurosci. 2020, Vol 14. |
[25] | Bellver-Landete, V. et al. Microglia are an essential component of the neuroprotective scar that forms after spinal cord injury. Nat. Commun. 2019, Vol 10. |
[26] | Kerstetter, A. E. & Miller, R. H. Isolation and culture of spinal cord astrocytes. Methods Mol. Biol. Clifton NJ. 2012, Vol 814, 93–104. |
[27] | Shie, J.-H. & Kuo, H.-C. Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int. 2011, Vol 198, E136-141. |
[28] | Lavelle, J. et al. Bladder permeability barrier: recovery from selective injury of surface epithelial cells. Am. J. Physiol. Renal Physiol. 2002, Vol 283, F242-253. |
[29] | Lewis, S. A., Berg, J. R. & Kleine, T. J. Modulation of epithelial permeability by extracellular macromolecules. Physiol. Rev. 1995, Vol 75, 561–589. |
[30] | Southgate, J. et al. Differentiation potential of urothelium from patients with benign bladder dysfunction. BJU Int. 2007, Vol 99, 1506–1516. |
[31] | Deckmann, K. et al. Bitter triggers acetylcholine release from polymodal urethral chemosensory cells and bladder reflexes. Proc. Natl. Acad. Sci. U. S. A. 2014, Vol 111, 8287–8292. |
[32] | Kullmann, F. A. et al. Serotonergic paraneurones in the female mouse urethral epithelium and their potential role in peripheral sensory information processing. Acta Physiol. 2018, Vol 222, e12919. |
[33] | Vannucchi, M.-G. & Traini, C. The telocytes/myofibroblasts 3-D network forms a stretch receptor in the human bladder mucosa. Is this structure involved in the detrusor overactive diseases? Ann. Anat. Anat. Anz. Off. Organ Anat. Ges. 2018, Vol 218, 118–123. |
[34] | Liu, Q. et al. Increased Piezo1 channel activity in interstitial Cajal-like cells induces bladder hyperactivity by functionally interacting with NCX1 in rats with cyclophosphamide-induced cystitis. Exp. Mol. Med. 2018, Vol 50, 1–16. |
[35] | Liu, Q. et al. Cyclophosphamide-induced HCN1 channel upregulation in interstitial Cajal-like cells leads to bladder hyperactivity in mice. Exp. Mol. Med. 2017, Vol 49, e319. |
[36] | Kuo, Y.-C. & Kuo, H.-C. Videourodynamic characteristics of interstitial cystitis/bladder pain syndrome-The role of bladder outlet dysfunction in the pathophysiology. Neurourol. Urodyn. 2018, Vol 37, 1971–1977. |
[37] | Lin, Y.-H., Chiang, B.-J. & Liao, C.-H. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders. Toxins. 2020, Vol 12. |
[38] | Bouchelouche, K., Nordling, J., Hald, T. & Bouchelouche, P. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. J. Urol. 2001, Vol 166, 1734–1737. |
[39] | Murray, E., Malley, S. E., Qiao, L.-Y., Hu, V. Y. & Vizzard, M. A. Cyclophosphamide induced cystitis alters neurotrophin and receptor tyrosine kinase expression in pelvic ganglia and bladder. J. Urol. 2004, Vol 172, 2434–2439. |
[40] | Lamb, K., Gebhart, G. F. & Bielefeldt, K. Increased nerve growth factor expression triggers bladder overactivity. J. Pain Off. J. Am. Pain Soc. 2004, Vol 5, 150–156. |
[41] | Charrua, A. et al. Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourol. Urodyn. 2015, Vol 34, 489–496. |
[42] | Liu, B. et al. Spinal astrocytic activation contributes to mechanical allodynia in a rat model of cyclophosphamide-induced cystitis. Mol. Pain. 2016, Vol 12. |
[43] | Majima, T. et al. Role of microglia in the spinal cord in colon-to-bladder neural crosstalk in a rat model of colitis. Neurourol. Urodyn. 2018, Vol 37, 1320–1328. |
[44] | Dogishi, K. et al. A rat long-lasting cystitis model induced by intravesical injection of hydrogen peroxide. Physiol. Rep. 2017, Vol 5. |
[45] | Chen, Y.-T. et al. Extracorporeal shock wave therapy ameliorates cyclophosphamide-induced rat acute interstitial cystitis though inhibiting inflammation and oxidative stress-in vitro and in vivo experiment studies. Am. J. Transl. Res. 2014, Vol 6, 631–648. |
[46] | Bouchelouche, K., Kristensen, B., Nordling, J., Horn, T. & Bouchelouche, P. Increased urinary leukotriene E4 and eosinophil protein X excretion in patients with interstitial cystitis. J. Urol. 2001, Vol 166, 2121–2125. |
[47] | Malik, S. T. et al. Distribution of mast cell subtypes in interstitial cystitis: implications for novel diagnostic and therapeutic strategies? J. Clin. Pathol. 2018, Vol 71, 840–844. |
[48] | Shie, J.-H., Liu, H.-T. & Kuo, H.-C. Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome. Urology. 2012, Vol 79, 484. e7-13. |
[49] | Kim, H. S. et al. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome. J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther. 2017, Vol 33, 530–538. |
[50] | Lee, J., Doggweiler-Wiygul, R., Kim, S., Hill, B. D. & Yoo, T. J. Is interstitial cystitis an allergic disorder?: A case of interstitial cystitis treated successfully with anti-IgE. Int. J. Urol. Off. J. Jpn. Urol. Assoc.2006, Vol 13, 631–634. |
[51] | Sun, Y. & Chai, T. C. Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis. Am. J. Physiol. Cell Physiol. 2006, Vol 290, C27-34. |
[52] | Chuang, Y. C. et al. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J. Urol. 2001, Vol 165, 975–979. |
[53] | Seki, S. et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J. Urol. 2002, Vol 168, 2269–2274. |
[54] | Tyagi, P. et al. Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J. Urol. 2012, Vol 187, 2243–2248. |
[55] | Byrne, D. S. et al. The urinary glycoprotein GP51 as a clinical marker for interstitial cystitis. J. Urol. 1999, Vol 161, 1786–1790. |
[56] | Tseng-Rogenski, S. & Liebert, M. Interleukin-8 is essential for normal urothelial cell survival. Am. J. Physiol. Renal Physiol. 2009, Vol 297, F816-821. |
APA Style
Sumargo, K. Z., Hasanuddin, A. D. I. (2024). Cellular and Molecular Aspect of Bladder Pain Syndrome: An Entry Point to Exploration of Its Pathogenesis. International Journal of Clinical Urology, 8(2), 12-18. https://doi.org/10.11648/j.ijcu.20240802.11
ACS Style
Sumargo, K. Z.; Hasanuddin, A. D. I. Cellular and Molecular Aspect of Bladder Pain Syndrome: An Entry Point to Exploration of Its Pathogenesis. Int. J. Clin. Urol. 2024, 8(2), 12-18. doi: 10.11648/j.ijcu.20240802.11
AMA Style
Sumargo KZ, Hasanuddin ADI. Cellular and Molecular Aspect of Bladder Pain Syndrome: An Entry Point to Exploration of Its Pathogenesis. Int J Clin Urol. 2024;8(2):12-18. doi: 10.11648/j.ijcu.20240802.11
@article{10.11648/j.ijcu.20240802.11, author = {Kuni Zakiyyah Sumargo and Abdi Dzul Ikram Hasanuddin}, title = {Cellular and Molecular Aspect of Bladder Pain Syndrome: An Entry Point to Exploration of Its Pathogenesis }, journal = {International Journal of Clinical Urology}, volume = {8}, number = {2}, pages = {12-18}, doi = {10.11648/j.ijcu.20240802.11}, url = {https://doi.org/10.11648/j.ijcu.20240802.11}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20240802.11}, abstract = {Background: Bladder pain syndrome/interstitial cystitis (BPS/IC) can cause pelvic pain, frequent urination, and a strong urge to urinate. These symptoms can significantly reduce quality of life, causing psychological distress, sexual dysfunction, poor sleep quality, decreased work productivity, and increased morbidity. Despite the prevalence of this condition, determining the most effective treatment guidelines for BPS/IC remains a challenge due to the complexity of its pathogenesis. Objective: Understanding cellular and molecular aspects is essential to explore different cell types in changes in function and sensitivity of the urothelial layer and chronic inflammation. Main Ideas: Cellular aspects in the pathogenesis of BPS/IC include Umbrella Cells, Basal and Intermediate Cells, Paraneuron Cells, Myofibroblasts and Telocytes, Detrusor Smooth Muscle Cells, Nerve Cells, Astrocytes, Microglia, CD68+ Macrophages, CD74+ Lymphocytes, Eosinophils, and Mast Cells. Disruption of these cells leads to altered urothelial barrier function, sensitivity, and chronic inflammation. Molecular aspects include chronic inflammation with increases in p38-mitogen activated protein kinase (p38 MAPK), Interleukin-1β (IL-1β), Interleukin-6 (IL-6), Tumor Necrosis Factor-α (TNF-α), Nerve Growth Factor (NGF), Brain-Derived Neurothropic Peptide (BDNF), and other molecules. Conclusion: Changes in the urothelial barrier and bladder wall sensitivity are also significant. Complex interactions between the immune and nervous systems contribute to chronic inflammation through positive feedback. Therefore, this article aims to understand the cellular and molecular aspects that play a role in the pathogenesis of BPS/IC and help provide appropriate treatment. }, year = {2024} }
TY - JOUR T1 - Cellular and Molecular Aspect of Bladder Pain Syndrome: An Entry Point to Exploration of Its Pathogenesis AU - Kuni Zakiyyah Sumargo AU - Abdi Dzul Ikram Hasanuddin Y1 - 2024/07/15 PY - 2024 N1 - https://doi.org/10.11648/j.ijcu.20240802.11 DO - 10.11648/j.ijcu.20240802.11 T2 - International Journal of Clinical Urology JF - International Journal of Clinical Urology JO - International Journal of Clinical Urology SP - 12 EP - 18 PB - Science Publishing Group SN - 2640-1355 UR - https://doi.org/10.11648/j.ijcu.20240802.11 AB - Background: Bladder pain syndrome/interstitial cystitis (BPS/IC) can cause pelvic pain, frequent urination, and a strong urge to urinate. These symptoms can significantly reduce quality of life, causing psychological distress, sexual dysfunction, poor sleep quality, decreased work productivity, and increased morbidity. Despite the prevalence of this condition, determining the most effective treatment guidelines for BPS/IC remains a challenge due to the complexity of its pathogenesis. Objective: Understanding cellular and molecular aspects is essential to explore different cell types in changes in function and sensitivity of the urothelial layer and chronic inflammation. Main Ideas: Cellular aspects in the pathogenesis of BPS/IC include Umbrella Cells, Basal and Intermediate Cells, Paraneuron Cells, Myofibroblasts and Telocytes, Detrusor Smooth Muscle Cells, Nerve Cells, Astrocytes, Microglia, CD68+ Macrophages, CD74+ Lymphocytes, Eosinophils, and Mast Cells. Disruption of these cells leads to altered urothelial barrier function, sensitivity, and chronic inflammation. Molecular aspects include chronic inflammation with increases in p38-mitogen activated protein kinase (p38 MAPK), Interleukin-1β (IL-1β), Interleukin-6 (IL-6), Tumor Necrosis Factor-α (TNF-α), Nerve Growth Factor (NGF), Brain-Derived Neurothropic Peptide (BDNF), and other molecules. Conclusion: Changes in the urothelial barrier and bladder wall sensitivity are also significant. Complex interactions between the immune and nervous systems contribute to chronic inflammation through positive feedback. Therefore, this article aims to understand the cellular and molecular aspects that play a role in the pathogenesis of BPS/IC and help provide appropriate treatment. VL - 8 IS - 2 ER -